188 results about "Mucoproteins" patented technology

The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.

Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.

The present invention provides a variant of an immunoglobulin variable domain including (A) at least one CDR region and (B) framework regions flanking the CDR region, wherein the variant also contains (a) a CDR region having added or substituted therein at least on binding sequence and (b) the flanking framework regions, wherein the binding sequence is heterelogous to the CDR and is an antigenic sequence from a MUC-1 binding sequence.

The invention relates to the technical field of cosmetics for skin beautifying, and particularly relates to an application of a mussel adhesive protein in preparing cosmetics for skin beautifying. The application disclosed by the invention has the following main beneficial effects: 1, after a mussel adhesive protein-containing cosmetic is applied on the skin, a molecular layer is formed on the skin, and after most of moisture is evaporated, because the mussel adhesive protein has a strong pyknosis effect, the mussel adhesive protein can promote the uniform shrinkage of the skin, so that the skin forms a uniform and consistent shrinkage layer, and then the occurrence of large wrinkles is avoided, thereby achieving the effect of instant skin firming and wrinkle removal, and improving the firmness and wrinkle resilience of the skin; 2, the smoothness and glossiness of the skin are increased; 3, the action of stains is reduced; and 4, the mussel adhesive protein is non-toxic and harmless.

New synthetic Lipid-A analogs based on monosaccharide (1) and disaccharide (2) derivatives were designed and prepared in the present invention. Both structures (1) and (2) incorporate novel lipid structures (3) and (4) that are not found in nature. Also, novel disaccharide Lipid-A structures (2) that incorporate novel contingents of uniform lipids and where R₁, R₄ and R₅ are the same substitution group of structure (III) were synthesized. Liposome formulations containing totally synthetic components such as synthetic Lipid-A and synthetic lipopeptide derived from tumor-associated MUC1 mucin are described along with their therapeutic utility. Comparative test results of immunostimulating properties and toxicity of Lipid-A analogs (1) and (2) are included.

The invention discloses a method for preparing a high-purity taste-removing purple sweet potato pigment, and belongs to the field of food additives and agricultural product deep processing. The method for preparing the high-purity taste-removing purple sweet potato pigment comprises the steps that 1, pretreatment is conducted on purple sweet potato raw materials; 2, the purple sweet potato pigment is extracted from low-frequency microwave auxiliary acidified aqueous solution; 3, preliminary purification is conducted on macroporous resins; 4, high-speed counter-current chromatography separation and purification are conducted, and the taste-removing purple sweet potato pigment with concentration more than 95% is obtained. According to the method for preparing the high-purity taste-removing purple sweet potato pigment, the microwave auxiliary acidified aqueous solution is used for extraction, flocculants are added to flocculate mucoproteins, then macroporous resin static adsorption and dynamic elution are conducted, and the taste-removing and enrichment purification process is preliminarily accomplished, and the high-purity taste-removing purple sweet potato pigment is finally prepared through the high speed counter-current chromatography method in a separation mode. According to the method for preparing the high-purity taste-removing purple sweet potato pigment, technological processes are advanced, separation efficiency is high, recovery rate is high, product purity is more than 95%, preparation amount is large, an obtained product is free of peculiar smell, has few impurities and is good in solubility, and method for preparing the high-purity taste-removing purple sweet potato pigment is easy to popularize and use.

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

The invention provides a process for extracting yam mucoproteins from yams and belongs to the field of extracting functional biological macromolecular substances from natural materials to produce functional healthcare food. The extracting process comprises the main steps of (1) material selection; (2) leaching gelatinization; (3) enzymolysis; (4) standing; (5) adjustment of PH value; (6) flocculation; (7) precipitation; and (8) drying. The yield of the yam mucoprotein products prepared by the process is 4 to 5 percent, and the content of yam mucoprotein is 60 to 67 percent. According to the process provided by the invention, the organic solvent extraction in the prior art is replaced by the flocculation and natural precipitation, so the product cost is greatly saved, the environmental pollution is lowered, and the process has great significance for actual production.

The invention relates to a chimeric antigen receptor and an expression gene thereof, a double-antigen regulated type T cell modified by the chimeric antigen receptor, and application thereof. The expression gene of the chimeric antigen receptor comprises a first fusion protein expression gene and a second fusion protein expression gene, wherein the first fusion protein expression gene comprises a mucoprotein-1 antibody expression gene, a notch receptor expression gene and a Gal4-VP64 transcription activating protein expression gene which are sequentially connected; the second fusion protein expression gene comprises a Gal4-UAS promoter expression gene and an anti-mesothelin expression gene which are sequentially connected. By adopting the innovative design, the chimeric antigen receptor has the advantages that the chimeric antigen receptor can be successfully imported into the T cell to form the T cell modified by the chimeric antigen receptor; the immune reaction cannot be produced until the mucoprotein-1 and the anti-mesothelin signals simultaneously exist, so as to reach the controllable immune reaction of the chimeric antigen receptor, fewer side effects in treatment, and high specificity.

The invention relates to the technical field of mucin 1 detection, in particular to a fluorescent biological probe for mucin 1 detection, a sensor, application and a detection method. In the present invention, the aptamer probe is used for an Exo I assisted target circulation (EATR) reaction. The hairpin probe comprises a hairpin probe H1 and a hairpin probe H2 which are used for GO-assisted hybridization chain reaction (HCR); the aptamer probe and the hairpin probe are combined to be used for mucin 1 detection, so organic combination of Exo I-assisted target circulation reaction and GO-assisted hybridization chain reaction can be realized; therefore, cascade amplification of fluorescence signals is realized, the detection sensitivity of mucoprotein 1 is remarkably improved, the detectionlimit is reduced, quantitative detection of low-concentration mucin 1 can be realized, and theprobe has high specificity and can be used for specifically identifying and detecting mucin 1.

The invention relates to the use of human bendazac lysine in pharmaceutical industry, wherein the bendazac lysine possesses substantial actions for reducing hypoglycemia and saccharifying hemoglobin and urine protein, thus can be applied to the prevention and treatment of diabetes.